

## 1174 SUMatriptan

sulfapyridine (60%), 5-aminosalicylic acid, metabolites (20%-33%); excreted in breast milk; crosses placenta

### INTERACTIONS

**Increase:** leukopenia risk—thiopurines (azaTHIOprine, mercaptopurine)

**Increase:** hypoglycemic response—oral hypoglycemics

**Increase:** anticoagulant effects—oral anticoagulants

**Decrease:** effect of cycloSPORINE, digoxin, folic acid

**Decrease:** renal excretion of methotrexate

### Drug/Food

**Decrease:** iron/folic acid absorption

### Drug/Lab Test

**False positive:** urinary glucose test

### NURSING CONSIDERATIONS

#### Assess:

• **Ulcerative colitis, proctitis, other inflammatory bowel disease:** character, amount, consistency of stools; abdominal pain, cramping, blood, mucus

• **Rheumatoid arthritis:** assess mobility, joint swelling, pain, ability to complete activities of daily living

• **Renal studies:** BUN, creatinine, urinalysis (long-term therapy)

• **Blood dyscrasias:** skin rash, fever, sore throat, bruising, bleeding, fatigue, joint pain; monitor CBC before therapy and q3mo

• **Allergic reaction:** rash, dermatitis, urticaria, pruritus, dyspnea, bronchospasm; identify sulfa, salicylate allergy

• **Pregnancy/breastfeeding:** use only if clearly needed; cautious use in breastfeeding, excreted in breast milk

#### Evaluate:

• Therapeutic response: absence of fever, mucus in stools, pain in joints

#### Teach patient/family:

• To take each oral dose with full glass of water to prevent crystalluria

• That contact lenses, urine, skin may be yellow-orange

• To avoid sunlight or use sunscreen to prevent burns

• **To notify prescriber of skin rash, sore throat, fever, mouth sores, unusual bruising, bleeding**

• That decreased sperm production may occur; that it resolves after completion of medication

• To notify prescriber if enteric-coated tablets are seen in stool; discontinue if present

### SUMatriptan (Rx)

(soo-ma-trip'tan)

ALSUMA Auto-injector, Imitrex, Imitrex DF 

Imitrex STAT-Dose, Sumavel DosePro, Onzetra Xsail, Zembrace SymTouch

*Func. class.:* Antimigraine agent

*Chem. class.:* 5-HT<sub>1</sub>B/D receptor agonist, abortive agent, triptan

#### Do not confuse:

SUMatriptan/somatropin

**ACTION:** Binds selectively to the vascular 5-HT<sub>1</sub>B/D receptor subtype; exerts antimigraine effect; causes vasoconstriction in cranial arteries

**USES:** Acute treatment of migraine with/without aura and cluster headache

### CONTRAINDICATIONS:

Angina pectoris, history of MI, documented silent ischemia, Prinzmetal's angina, ischemic heart disease, IV use, concurrent ergotamine-containing preparations, uncontrolled hypertension, hypersensitivity, basilar or hemiplegic migraine

**Precautions:** Pregnancy, breastfeeding, children <18 yr, geriatric patients, postmenopausal women, men >40 yr, risk factors for CAD, hypercholesterolemia, obesity, diabetes, impaired renal/hepatic function, overuse

### DOSAGE AND ROUTES

• **Adult:** SUBCUT ≤6 mg; may repeat in 1 hr; max 12 mg/24 hr; PO 25 mg with fluids, if no relief in 2 hr, give another